UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-41380 Bausch + Lomb Corporation (Exact name of registrant as specified in its charter) Canada 98-1613662 (State or other ...

Bausch + Lomb Corporation (NYSE:BLCO) Q3 2024 Results Conference Call October 30, 2024 8:00 AM ET Company Participants George Gadkowski - Vice President of Investor Relations and Business Insights Brenton Saunders - CEO & Chairman Osama Eldessouky - Executive VP & CFO Conference Call Participants Patrick Wood - Morgan Stanley Xuyang Li - Jefferies Matt Miksic - Barclays Doug Miehm - RBC Capital Markets Lilia-Celine Lozada - JPMorgan Operator Good morning and welcome to Bausch + Lomb's Third Quarter 2024 Ear ...

For the quarter ended September 2024, Bausch + Lomb (BLCO) reported revenue of $1.2 billion, up 18.8% over the same period last year. EPS came in at $0.17, compared to $0.22 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $1.17 billion, representing a surprise of +2.54%. The company delivered an EPS surprise of +6.25%, with the consensus EPS estimate being $0.16. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall St ...

Bausch + Lomb (BLCO) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.22 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 6.25%. A quarter ago, it was expected that this company would post earnings of $0.13 per share when it actually produced earnings of $0.13, delivering no surprise. Over the last four quarters, the company has surpas ...

Exhibit 99.1 Bausch + Lomb Announces Third-Quarter 2024 Results • Revenue of $1.196 Billion • GAAP Net Income Attributable to Bausch + Lomb Corporation of $4 Million • Adjusted EBITDA (non-GAAP) of $212 Million; Adjusted EBITDA excluding Acquired IPR&D (nonGAAP) of $227 Million • Revenue Grew 19% as Reported and 19% on a Constant Currency Basis Compared to the Third Quarter of 2023, Driven by Solid Execution and Growth Across All Segments • Raising Full-Year 2024 Revenue Guidance 1 1 1 VAUGHAN, Ontario, Oct ...

It was quite a busy and eventful day for the company. Monday was an eventful day for Bausch + Lomb (BLCO 7.19%). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval. As if that weren't enough, media reports claimed that the company has put itself up for sale. Buffeted by these strong winds, Bausch + Lomb's stock price rose over 7% in the day's trading session. Eyes on the prize Of the two news items, the buyout one had the bigger i ...

This week, the Federal Reserve's decision to reduce interest rates by 50 basis points boosted share prices across the technology, construction, industrial, machinery, and financial sectors. These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio? Also Read: Photo by JHVEPhoto via Shutterstock ...

Bausch + Lomb (BLCO) shares ended the last trading session 14.5% higher at $17.80. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.8% loss over the past four weeks. Bausch + Lomb scored a strong price increase on investors' optimism surrounding a Financial Times report stating that the company is contemplating a sale to address challenges related to its spin-off from the parent company Bausch Health. Private equi ...

The highly indebted healthcare stock rose on rumors it may be selling itself. Shares of Bausch + Lomb (BLCO 15.63%) rallied 15.7% as of 3:07 p.m. ET today. The stock is surging today on news the company is considering selling itself. Of note, Bausch + Lomb is the eye-care subsidiary of Bausch Health Companies, which was formerly known as Valeant Pharmaceuticals. Bausch Health prefers cash, not shares Valeant got into trouble nearly a decade ago after using debt to buy up several pharmaceutical companies, th ...

Key Takeaways Bausch + Lomb is discussing a possible sale that would separate it from its parent company, Bausch Health Cos. Bausch Health is saddled with debt of $21 billion, nearly $10 billion of which is set to mature in 2027. In July, Bausch Health pushed back against a research firm's report that said it was mulling bankruptcy options. Bausch + Lomb (BLCO) shares popped Monday following a report that the eyecare company is considering a sale. The contact lens producer is working with Goldman Sachs (GS) ...